Urology Doctors in Manhattan, KS Accepting Medicare

5 Urology doctors found. Showing 1 - 5

Fred A Freeman, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1133 College Ave, C200, Manhattan, KS 66502 Phone: 785-537-8710    Fax: 785-537-0562

John P Devine, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1133 College Ave, G100, Manhattan, KS 66502 Phone: 785-537-8710    Fax: 785-537-0562

Felipe Rosso, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1133 College Ave Ste G100, Associated Urologists Pa, Manhattan, KS 66502 Phone: 785-537-8710    Fax: 785-537-0562

Carl T Newman, M.D. Urology Medicare: Medicare Enrolled Practice Location: 1220 Marlatt Ave, Manhattan, KS 66502 Phone: 785-539-1787    Fax: 785-539-0890

Apostolos Evangelidis, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1133 College Ave, Manhattan, KS 66502 Phone: 785-537-8710    Fax: 785-537-0532

News Archive

New research measures direct radiation doses in patients during endovascular procedures

New research published in the April 2011 issue of the Journal of Vascular Surgery®, the official publication of the Society for Vascular Surgery®, directly measured the radiation doses for patients and operators during complex endovascular procedures.

Gene that prevents cancer also controls the skin's suntanning machinery

"The p53 tumor suppressor is commonly mutated in human cancer," explained David Fisher, director of the Melanoma Program in Medical Oncology at Dana-Farber Cancer Institute. "Now, we've found that it plays a role in the skin's tanning response."

Centre for Life opens with the UK's first two human embryonic stem cell lines

The UK's first two human embryonic stem cell lines, developed separately by researchers at King's College London and the Centre for Life in Newcastle, are to be deposited in the UK Stem Cell Bank. The deposit coincides with the official opening of the Bank by Health Minister, Lord Warner, today (Wednesday 19 May 2004).

Adamas begins ADS-5102 Phase 2/3 clinical trial in Parkinson's disease

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.

Read more Medical News

› Verified 3 days ago